Search - tctmd.com

Displaying 161 - 180 of 390

Sort: Relevancy | Date

Presentation TCT 2016

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Ashok Seth

October 31, 2016

Presentation TCT 2016

FANTOM II: Six-Month and Nine-Month Clinical and Angiographic Results With a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Alexandre Abizaid

October 31, 2016

Presentation TCT 2016

REVELUTION: Nine-Month Clinical, Angiographic, IVUS, and OCT Outcomes With a Polymer-Free Sirolimus-Eluting Drug-Filled Stent

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Stephen G. Worthley

October 31, 2016

Presentation TCT 2016

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

Presenter: John A. Bittl, Daniel I. Simon, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

Have Contemporary DES Narrowed the Gap With CABG in Multivessel Disease? From BEST to SYNTAX II and Beyond

Presenter: Dean J. Kereiakes, Pieter C. Smits, Patrick W. Serruys

October 30, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

Presentation TCT 2016

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Patrick W. Serruys

October 30, 2016

News Conference News ESC 2016

Use of Antithrombotics Instead of Stents Appears Safe, Reduces Thrombus Burden in Subset of ACS Patients: EROSION

Michael O'Riordan

August 30, 2016

News Daily News

现代 PCI 当中加入 SYNTAX 评分 II 对三支病变患者有益

Caitlin E. Cox

May 26, 2016

News Daily News

SYNTAX Score II Added to Modern PCI Translates Into Gains for Patients With Three-Vessel Disease

Caitlin E. Cox

May 26, 2016

News Daily News

La Escala del SYNTAX II Incorporada a las Modernas PCI se Traduce en Beneficios para Pacientes con Enfermedad de 3 Vasos

Caitlin E. Cox

May 26, 2016

News Conference News EuroPCR 2016

Valvular Interventions for the Asymptomatic and Low Risk: Coming Soon to a Cath Lab Near You?

Yael L. Maxwell

May 20, 2016

Presentation EuroPCR 2016

Early Percutaneous Intervention for Valvular Disease …An Opportunity for Improving Patient’s Outcome

Presenter: Patrick Serruys

May 20, 2016

News Industry News

Micell Technologies Completes Enrollment in OCT Study Designed to Evaluate Superior Performance of MiStent SES Compared to Xience

March 22, 2016

Presentation JIM 2016

Complications after BRS Frequency, Mechanism and Differences from metallic DES

Presenter: Patrick W. Serruys

February 09, 2016

News Daily News

It’s Official: Europe Bans Direct Industry Sponsorship of Physicians for CME

Todd Neale

December 02, 2015

News Daily News

Amid Push-Back, Direct Industry Sponsorship of Physicians on Its Way Out in Europe

Todd Neale

November 25, 2015

Presentation TCT 2015

When and How Should We Use a Dedicated Stent for Left Main PCI (With Case Examples)?

Presenter: Nicholas J. Lembo, Patrick W. Serruys, Eulogio J. Garcia

October 15, 2015

Presentation TCT 2015

Left Main Stent Technique and Decision Making: What We Have Learned From the ISAR LEFT Main I and II Trials

Presenter: Nicholas J. Lembo, Patrick W. Serruys, Julinda Mehilli

October 15, 2015

Presentation TCT 2015

Left Main Stent Technique and Decision Making: What We Have Learned From the DELTA Registry

Presenter: Nicholas J. Lembo, Patrick W. Serruys, Alaide Chieffo

October 15, 2015

Advertisement

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

FANTOM II: Six-Month and Nine-Month Clinical and Angiographic Results With a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

REVELUTION: Nine-Month Clinical, Angiographic, IVUS, and OCT Outcomes With a Polymer-Free Sirolimus-Eluting Drug-Filled Stent

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

Have Contemporary DES Narrowed the Gap With CABG in Multivessel Disease? From BEST to SYNTAX II and Beyond

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Use of Antithrombotics Instead of Stents Appears Safe, Reduces Thrombus Burden in Subset of ACS Patients: EROSION

现代 PCI 当中加入 SYNTAX 评分 II 对三支病变患者有益

SYNTAX Score II Added to Modern PCI Translates Into Gains for Patients With Three-Vessel Disease

La Escala del SYNTAX II Incorporada a las Modernas PCI se Traduce en Beneficios para Pacientes con Enfermedad de 3 Vasos

Valvular Interventions for the Asymptomatic and Low Risk: Coming Soon to a Cath Lab Near You?

Early Percutaneous Intervention for Valvular Disease …An Opportunity for Improving Patient’s Outcome

Micell Technologies Completes Enrollment in OCT Study Designed to Evaluate Superior Performance of MiStent SES Compared to Xience

Complications after BRS Frequency, Mechanism and Differences from metallic DES

It’s Official: Europe Bans Direct Industry Sponsorship of Physicians for CME

Amid Push-Back, Direct Industry Sponsorship of Physicians on Its Way Out in Europe

When and How Should We Use a Dedicated Stent for Left Main PCI (With Case Examples)?

Left Main Stent Technique and Decision Making: What We Have Learned From the ISAR LEFT Main I and II Trials

Left Main Stent Technique and Decision Making: What We Have Learned From the DELTA Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content